



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

11th February 2026
IOLCP/CGC/2026

National Stock Exchange of India Ltd

Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051

Security Symbol: IOLCP

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai – 400 001

Security Code: 524164

Subject: Press Release – Financial Results for the quarter and nine months ended 31st December 2025

Dear Sir,

Pursuant to Regulation 30 read with Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, please find enclosed a Press Release dated 11th February 2026 with respect to financial results for the quarter and nine months ended 31st December 2025.

Hope you will find the same in order.

Thanking You,

Yours faithfully,
for IOL Chemicals and Pharmaceuticals Limited

Abhay Raj Singh
Sr. Vice President & Company Secretary

IOL Chemicals and Pharmaceuticals Limited Reports Q3 & 9M FY26 Results
PBT (Before Exceptional Items) Up 39% YoY, Alongside Margin Expansion

Ludhiana, 11th February 2026: IOL Chemicals & Pharmaceuticals Ltd., one of the leading Active Pharmaceutical Ingredient (API) manufacturers, announced its Financial Results for the quarter and nine months ended 31st December 2025.


Q3 FY26 Financial Performance Snapshot (Y-o-Y)
(Standalone)

Revenue from Operations	EBITDA	PBT*
₹ 580.4 Cr	₹ 62.6 Cr	₹ 38.8 Cr
▲ 10.9%	▲ 22.8%	▲ 39.3%

Key Standalone Financial Highlights

Particulars (₹ Cr)	Q3 FY26	Q3 FY25	Y-o-Y	9M FY26	9M FY25	Y-o-Y
Revenue from Operations	580.4	523.3	+10.9%	1,699.6	1,551.4	9.6%
EBITDA	62.6	50.9	+22.8%	196.1	157.1	24.8%
EBITDA Margin (%)	10.7%	9.7%	+102 bps	11.4%	10.0%	+139 bps
PBT*	38.8	27.8	+39.3%	124.8	93.0	+34.2%
PBT Margin (%)*	6.6%	5.3%	+134 bps	7.3%	5.9%	+134 bps

* PBT and PBT Margin are calculated after netting off exceptional items arising from new labour laws.

Segment Highlights
(In ₹ Cr)


Commenting on the performance, Mr Vikas Gupta, Joint Managing Director said,

“Q3 FY26 has been a resilient quarter for IOL, marked by double-digit revenue growth, margin expansion, and a 39% YoY increase in profit before exceptional items and tax, despite prevailing geopolitical uncertainties. This performance underscores the resilience of our operations and sustained demand across our businesses.

Our Pharmaceuticals segment continues to lead growth, delivering an 18% revenue increase year-on-year. Importantly, pharma’s share of overall revenue has risen from 57% in Q3 FY25 to 61% in Q3 FY26, highlighting its growing contribution. EBIT from Pharmaceuticals grew 32% YoY, driven by healthy volume growth and strong traction in non-Ibuprofen APIs, which are broadening and diversifying our product portfolio.

In Chemicals, we achieved optimal capacity utilisation, reflecting improved demand and operational discipline. EBIT grew 37% YoY, supported by efficiency gains and sustained customer traction. This validates the strength of our diversified business model and the meaningful contribution of both segments.

Looking ahead, our focus remains on expanding our presence in regulated markets, strengthening our new product pipeline, deepening backward integration, and enhancing R&D capabilities. These measures will help us sustain growth momentum, enhance competitiveness, and deliver long-term value creation for our stakeholders”

About IOL Chemicals and Pharmaceuticals Ltd.

IOL Chemicals and Pharmaceuticals Ltd. (IOLCP), established in 1986 and headquartered in Ludhiana, Punjab, is a leading Indian manufacturer of Active Pharmaceutical Ingredients (APIs) and specialty chemicals. It is the world’s largest producer of Ibuprofen with a 30% global market share, among the largest global producers of Iso Butyl Benzene (IBB), and a key manufacturer of Ethyl Acetate in India. IOLCP’s API portfolio spans key therapeutic areas such as pain management, anti-convulsants, anti-diabetics, and cardiovascular care. With exports to over 80 countries—including the USA, UK, China, and Germany—and strong regulatory approvals, the company is well-positioned for global growth. Its backward-integrated operations and ongoing capacity expansion support long-term scalability and resilience.



Contact Details

IOL Chemicals & Pharmaceuticals Ltd.	Investor Relations: MUFG Intime India Pvt. Ltd.
	
CIN: L24116PB1986PLC007030	Ms. Prachi Ambre prachi.ambre@in.mpms.mufg.com
Mr. Abhay Raj Singh Sr. VP & Company Secretary investor@iolcp.com	Mr. Irfan Raeen irfan.raeen@in.mpms.mufg.com Meeting Request Link Website: https://in.mpms.mufg.com/

Safe Harbor Statement

Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company's operations include a downtrend in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections, interest, and other costs. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.